Nonstatin Drugs (WB Borden, Section Editor)

Current Atherosclerosis Reports

, 15:292

Lipid Effects of Psychiatric Medications

  • Junzo WatanabeAffiliated withDepartment of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences
  • , Yutaro SuzukiAffiliated withDepartment of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences
  • , Toshiyuki SomeyaAffiliated withDepartment of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

People with schizophrenia have higher rates of medical illness and mortality than the general population. Cardiovascular disease is a major contributor to premature death in patients with schizophrenia. There has been an increase literature discussing the high prevalence of dyslipidemia, which is one of risk factors for cardiovascular disease, induced by second generation antipsychotic agents. Depression is associated with increased risks of diabetes, hypertension, cardiovascular disease. However, those may not be secondary to the use of antidepressant agents. In order to reduce the risk of cardiovascular disease in patients with schizophrenia receiving antipsychotic agents, obtaining fasting lipid measurements at regular intervals is needed. Further investigations are needed to evaluate the effects of antidepressive agents on lipid profiles.

Keywords

First generation antipsychotic agents Second generation antipsychotic agents Antidepressive agents Dyslipidemia Lipid profiles Monitoring